How do we treat #VEXAS - UBA1 mutation Large multicenter cohort - 110 pts, 99% M Confirms the benefit of JAKi and tocil
Tweet Content
How do we treat #VEXAS - UBA1 mutation
Large multicenter cohort - 110 pts, 99% M
Confirms the benefit of JAKi and tocilizumab
Others not so much
@RheumNow #ACR23 #ACRBest
#abstL03 https://t.co/tRjO31IHiD
Show on Archive Page
On
Display in Search Results
On
PDQ
Off